Featured Session | Biotech Business Models and Financing Strategy
Business Model and Financial Strategy Decisions Licensing, M&A, partnering, scaling-up, IPO and more!
The pathways are many, the risks are varied, but the choices made early on will be critical to the future success of a growing biotech company. In this session, we have invited industry veterans and heavyweight speakers to advise on making important decisions around business model development and strategy.
Swimming with Sharks: Early Stage Biotechnology Business Models and Financing Strategies
Dr. Carter will give a talk about bioindustry development cycles and introducing the challenges and opportunities for all early-stage companies.
Building a Biotechnology Company through Collaboration, Licensing and M&A
Mr. Grady will address why AstraZeneca set up an innovation center in China while most western big pharma retreated. What strategies, pipelines, or disease areas so far and what can we expect from these strategies?
Dr. Li is a Venture Partner with Lilly Asia Ventures. He was most recently Executive VP and Global Head of Business Development at BeiGene; prior to that, he was VP of Business Development and Licensing at Merck and Executive Director of External R&D at Amgen. With over 21 years of industry experience, he will be sharing his investment strategy and insights.
Mr. McCracken will share his insight regarding Genentech has leveraged academic collaborations, in-licensing, out-licensing, and M&A to discover and bring its innovative medicines to patients.
Online @ BIO Asia–Taiwan, July 23.
15:40-17:10 Taipei Time
Don't miss your chance to join thousands of bioindustry professionals from Asia and around the world at BIO Asia–Taiwan 2020 Online + Live!